475.16
-1.57 (-0.33%)
| Previous Close | 476.73 |
| Volume | 9,096 |
| Price / Earnings (Forward) | 27.29 |
| Price / Sales | 6.89 |
| Price / Book | 2.94 |
| 52 Weeks Range |
| Profit Margin | 22.02% |
| Operating Margin (TTM) | 22.93% |
| Diluted EPS (TTM) | 11.01 |
| Quarterly Revenue Growth (YOY) | 3.90% |
| Quarterly Earnings Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 78.58% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | 758.81 M |
| Levered Free Cash Flow (TTM) | 588.83 M |
| Return on Assets (TTM) | 11.61% |
| Return on Equity (TTM) | 40.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Waters Corporation | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 2.7 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 2.7 |
| Timing 35% | 3.0 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | 1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×0.95 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | +37.0% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -3.0 |
| Final Score | 2.36 |
Select this tab to load the latest available analysis.
|
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 98.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fundsmith Llp | 30 Jun 2026 | 2,273,632 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |